Skip to main content
Equibles

BLRX · BioLineRx Ltd.

Track BLRX — free

Use BLRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.67 -0.02 (-0.74%) At close · Sep 4
Rebalance outlook locked
Market Cap
$12.95M
Shares
4.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.67 Open$2.72 Day$2.55–2.72 52W close$2.18–4.44 Avg vol 30d20K Short int135K · 2.8% float · 19.8d Short vol31% Last earningsSep 30, 2025 DataJan 2025–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Jan 30, 2025; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-24.8%
Trailing year
Short interest
2.8%
Latest settlement · 19.8 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg −7%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 22%
mid-range
Momentum
relative strength
Weak
1-month return −1%
trailing
6-month return +2%
trailing
YTD return −4%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.78% of float · ▼ -0.2% MoM · 19.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −51%
past year
ATR 8.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
22% Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.78% of float · ▼ -0.2% MoM · 19.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 22% Range high $4
vs 200-day avg -8% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BLRX
BioLineRx Ltd.
this stock
$12.95M -3.6% — — 2.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
14
% held
2.2%
Net QoQ
+75.8K sh
Top holder
SUSQUEHANNA INTERNATIONAL…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
134.6K
Days to cover
19.8d
Change
-264 sh
View
Short Volume
Short vol %
31%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
7
Value
$19
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
50.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 31, 2026
This year
14
View
Exempt Offerings
Offering
$9.0M
Filed
Jun 10, 2020
View
Earnings & Events
Earnings Calls
Last call
Sep 30, 2025
View

Performance

Raw-price comparisons begin at the captured split on Jan 30, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BLRX +2.7% -1.5% +1.5% -4.6% -3.6%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +2.6% -1.1% -13.6% -5.1% -16.6%
Key facts CIK 1498403 CUSIP 09071M304 13F (30d) 11 filings 11 filers Visit website Investor relations